Literature DB >> 663186

Voice change after radiotherapy. Some preliminary results.

R H Colton, R H Sagerman, C T Chung, Y W Yu, G F Reed.   

Abstract

A one-third octave spectral analysis was performed on two sentences spoken by 5 patients with laryngeal cancer, 5 with head/neck cancer not involving the vocal cords, and 12 normal subjects. Recordings were made prior to and at weekly intervals during radiotherapy as well as at periodic intervals post-treatment. Patients with laryngeal cancer exhibited lower spectral levels than normal throughout radiotherapy as well as several months post-treatment. By one year after treatment, the spectral levels of these patients were largely in the normal range. Patients with head/neck cancer not involving the vocal cords exhibited greater than normal sound pressure levels throughout most of the spectrum. These levels remained high even at one month post-treatment. Irradiation of normal vocal cord tissue also seems to result in higher spectral levels.

Entities:  

Mesh:

Year:  1978        PMID: 663186     DOI: 10.1148/127.3.821

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Quantitative analysis of voice quality in early glottic laryngeal carcinomas treated with radiotherapy.

Authors:  A S Dagli; H F Mahieu; J M Festen
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

2.  Co-Occurrence of Hypernasality and Voice Impairment in Amyotrophic Lateral Sclerosis: Acoustic Quantification.

Authors:  Marziye Eshghi; Kathryn P Connaghan; Sarah E Gutz; James D Berry; Yana Yunusova; Jordan R Green
Journal:  J Speech Lang Hear Res       Date:  2021-10-29       Impact factor: 2.674

3.  Acoustic voice analysis in different phonetic contexts after larynx radiotherapy for T1 vocal cord carcinoma.

Authors:  Angeles Rovirosa; Carlos Ascaso; Rosa Abellana; Eugenio Martínez-Celdrán; Alicia Ortega; Mercedes Velasco; Montserrat Bonet; Teresa Herrero; Meritxell Arenas; Albert Biete
Journal:  Clin Transl Oncol       Date:  2008-03       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.